About Rodin Therapeutics
Rodin Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2013, and was acquired by Alkermes in November 2019. Epigenetic modulators are developed for CNS disorder treatments. Rodin Therapeutics has raised $57.2 million across 5 funding rounds from investors including Biogen, Alkermes and HHS. The company has 13 employees. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is RODIN THERAPEUTICS, INC. Its competitors include Biogen, Neurocrine and PTC Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Rodin Therapeutics was founded in 2013 and is headquartered in Cambridge, United States. Focus is placed on the biotechnology sector, where epigenetic modulators are developed for addressing central nervous system disorders. Epigenetic regulation is achieved through HDAC complex modulation, by which synaptic function, neuronal health, and survival are restored in degenerative brain diseases. Operations center on research and therapeutic development in this field.
- Headquarters Cambridge, United States
- Employees 13
- Stage Acquired
- SectorsHealthcare
- Website rodintherapeutics.com
- Social LinkedIn X
- Acquired by Alkermes (Nov 2019)
- Legal Name Rodin Therapeutics, Inc
Funding Insights of Rodin Therapeutics
Rodin Therapeutics has successfully raised a total of $57.2M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $27 million completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $57.2M
- Total Rounds 5
- Last Round Series C — $27M
- Investors Count 8
All 5 funding rounds of Rodin Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2017 | $27M | Series C | – | – | |
| Jan 2016 | $17.3M | Series B | – | – | |
| Jun 2015 | $217,210 | Grant | – | – | |
| May 2014 | $12.9M | Series A | – | Johnson & Johnson Innovation – JJDC, Atlas Venture | – |
| Jun 2013 | Seed | – | – |
9 investors in total: 9 institutional.
Investors in Rodin Therapeutics
Rodin Therapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, Alkermes and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe | hatterasvp.com | Durham, United States | ||
| remeditex.com | ||||
Corporate-backed venture capital is focused on fintech and multiple sectors. | thirdpointventures.com | Menlo Park, United States | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Therapies for neurodegenerative and immunology disorders are developed. | 1978 | biogen.com | Cambridge, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Developer of small molecule therapeutics and drug delivery technologies for multiple CNS diseases | 1987 | alkermes.com | Dublin, Ireland |
Investor details for Rodin Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Rodin Therapeutics
4 dated milestones of Rodin Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Rodin Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $27.0M.
- Exit Acquired by Alkermes.
Competitors of Rodin Therapeutics
Rodin Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, Neurocrine and PTC Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of Rodin Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Rodin Therapeutics (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rodin Therapeutics
Complete news archive for Rodin Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rodin Therapeutics
Rodin Therapeutics was founded in 2013.
Rodin Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Rodin Therapeutics is a funded company, having raised a total of $57.2M across 5 funding rounds to date.
Rodin Therapeutics has 13 employees.
Rodin Therapeutics was founded in 2013 and is headquartered in Cambridge, United States. Focus is placed on the biotechnology sector, where epigenetic modulators are developed for addressing central nervous system disorders. Epigenetic regulation is achieved through HDAC complex modulation, by which synaptic function, neuronal health, and survival are restored in degenerative brain diseases. Operations center on research and therapeutic development in this field.
Rodin Therapeutics's top competitors include PTC Therapeutics, Neurocrine and Biogen.
Rodin Therapeutics has 9 investors. Key investors include Biogen, Alkermes, HHS, Atlas Venture, and Google Ventures.
Rodin Therapeutics operates through Rodin Therapeutics, Inc.
Yes. Rodin Therapeutics was acquired by Alkermes in November 2019.